Citadel Advisors’s Aspire Biopharma ASBP Stock Holding History

Citadel Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22	Closed	-$15.7K	–	15704
2025 Q1	$15.7K	Buy	+22	New	+$152K	﹤0.01%	13305

Other funds holding ASBP

Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VAS

VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return

TSW

Three Seasons Wealth Salt Lake City, Utah $262M AUM 45.03% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ASBP Position: Q2 2025 in Review

Citadel Advisors sold out of Aspire Biopharma (ASBP) in Q2 2025, closing a stake of 22 shares — an estimated $15.7K sold.

Citadel Advisors first reported a position in ASBP in Q1 2025 and held it in 1 quarter. The position peaked at $15.7K in Q1 2025. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2025.

Citadel Advisors reported no remaining Aspire Biopharma position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 22 Aspire Biopharma shares in Q2 2025, an estimated $15.7K.
Citadel Advisors first reported a position in Aspire Biopharma in Q1 2025 and held it in 1 quarter.
Citadel Advisors's Aspire Biopharma position peaked at $15.7K in Q1 2025.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.